MX2020004058A - Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos. - Google Patents

Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.

Info

Publication number
MX2020004058A
MX2020004058A MX2020004058A MX2020004058A MX2020004058A MX 2020004058 A MX2020004058 A MX 2020004058A MX 2020004058 A MX2020004058 A MX 2020004058A MX 2020004058 A MX2020004058 A MX 2020004058A MX 2020004058 A MX2020004058 A MX 2020004058A
Authority
MX
Mexico
Prior art keywords
amino acid
therapeutic uses
acid oxidase
oxidase inhibitors
inhibitors
Prior art date
Application number
MX2020004058A
Other languages
English (en)
Inventor
Guochuan Emil Tsai
Ching - Cheng WANG
Yuan - Ting Hsieh
Original Assignee
Syneurx Int Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syneurx Int Taiwan Corp filed Critical Syneurx Int Taiwan Corp
Publication of MX2020004058A publication Critical patent/MX2020004058A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos de formula (I): (Ver Fórmula). o una sal farmacéuticamente aceptable del mismo, en la que: cada uno de A, B, C, D y E, independientemente, es C, N, N-H, O, S o está ausente; es un enlace simple o un enlace doble; cada uno de X, Y y Z, independientemente, es arilo, heteroarilo, aralquilo, H o ausente; cada uno de L1 y L2, independientemente, es un radical seleccionado de O, CH2, C=O, alquilo de C2-10, alquenilo de C2-10, alquinilo de C2-10, -((CH2)nW)-, en donde n=0, 1, 2, 3, 4 o 5, y W es O o S, o está ausente; y cuando L2 está ausente, Z es arilo o heteroarilo fusionado con B C; también se proporciona en la presente invención un método para inhibir, tratar y/o reducir el riesgo de un trastorno neuropsiquiàtrico, que comprende administrar a un sujeto y necesita una composición que comprenda un compuesto de formula (I).
MX2020004058A 2017-10-18 2018-10-18 Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos. MX2020004058A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/787,557 US10336724B2 (en) 2017-10-18 2017-10-18 D-amino acid oxidase inhibitors and therapeutic uses thereof
PCT/CN2018/110763 WO2019076329A1 (en) 2017-10-18 2018-10-18 INHIBITORS OF D-AMINO ACID OXIDASE AND THERAPEUTIC APPLICATIONS THEREOF

Publications (1)

Publication Number Publication Date
MX2020004058A true MX2020004058A (es) 2020-07-21

Family

ID=66095590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004058A MX2020004058A (es) 2017-10-18 2018-10-18 Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.

Country Status (10)

Country Link
US (1) US10336724B2 (es)
EP (1) EP3697763A4 (es)
JP (1) JP2020537656A (es)
KR (1) KR20200085769A (es)
CN (1) CN111479806B (es)
CA (1) CA3079042A1 (es)
IL (1) IL273922B1 (es)
MX (1) MX2020004058A (es)
TW (1) TWI709557B (es)
WO (1) WO2019076329A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP3960168A1 (en) 2020-08-28 2022-03-02 Université de Genève Compositions and methods comprising d-cysteine or a derivative thereof
CN114965720B (zh) * 2021-02-20 2024-02-23 成都康弘药业集团股份有限公司 一种测定氢溴酸伏硫西汀有关物质的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA2552098A1 (en) * 2003-12-29 2005-07-21 Sepracor Inc. Benzo[d]isoxazol-3-ol daao inhibitors
JP2007517056A (ja) * 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールｄａａｏ阻害剤
US8183398B2 (en) * 2008-02-25 2012-05-22 Eastman Chemical Company 5-hydroxy-2-methyl-4H-pyran-4-one esters as novel tyrosinase inhibitors
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
GB201111704D0 (en) * 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
CN103667245B (zh) 2013-11-21 2015-08-19 中国科学院化学研究所 一种固定d-氨基酸氧化酶的方法
CN106749045B (zh) 2017-03-03 2020-02-14 上海交通大学 一种d-氨基酸氧化酶抑制剂及其制法和应用

Also Published As

Publication number Publication date
WO2019076329A9 (en) 2019-08-15
TWI709557B (zh) 2020-11-11
CN111479806A (zh) 2020-07-31
WO2019076329A1 (en) 2019-04-25
RU2020115863A (ru) 2021-11-18
US20190112289A1 (en) 2019-04-18
JP2020537656A (ja) 2020-12-24
US10336724B2 (en) 2019-07-02
TW201922725A (zh) 2019-06-16
IL273922A (en) 2020-05-31
CA3079042A1 (en) 2019-04-25
EP3697763A1 (en) 2020-08-26
EP3697763A4 (en) 2021-06-09
IL273922B1 (en) 2024-08-01
RU2020115863A3 (es) 2021-11-26
KR20200085769A (ko) 2020-07-15
CN111479806B (zh) 2024-01-30

Similar Documents

Publication Publication Date Title
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
MX2022004304A (es) Agentes inductores de apoptosis.
MX2020003596A (es) Composiciones de acido nucleico-polipeptido y usos de las mismos.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MX2020004708A (es) Sistema y metodos de transporte.
CA2956871C (en) Compounds active towards bromodomains
MX2024008096A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2020003760A (es) Formulaciones de niraparib.
MX2020003483A (es) Composiciones de pienso para animales mejoradas y metodos de uso.
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2020004424A (es) Formulacion aerosolizable.
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
MX2020004241A (es) Conector y montaje de conector.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
SG10201808278TA (en) Polishing composition and polishing method
MX2019015676A (es) Uso de isovaleril espiramicina i, ii y/o iii en la fabricación de medicamentos para el tratamiento y/o la prevención de tumores, y el medicamento.
PL3645016T3 (pl) Połączenie zawierające tlen i kwas hialuronowy do stosowania miejscowego-dopochwowego
MX2020012893A (es) Formulaciones de proteinas.
EP3731840A4 (en) NADPH OXIDASE INHIBITORS AND THEIR USE
MX2020004058A (es) Inhibidores de d-aminoacido oxidasa y sus usos terapeuticos.
MX2019013096A (es) Peptidos para el tratamiento de diabetes.
ZA202211980B (en) Methods and treatment of trauma
MX2020003768A (es) Composiciones acuosas herbicidas y metodos para usar las mismas.